Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Noxopharm and Hudson Institute collaborate on pioneering mRNA research

Published 12/10/2023, 12:49 pm
Updated 12/10/2023, 01:30 pm
© Reuters.  Noxopharm and Hudson Institute collaborate on pioneering mRNA research

In a recent interview, Noxopharm Ltd (ASX:NOX, OTC:NOXOF)’s CEO Dr Gisela Mautner joins Proactive alongside Associate Professor Michael Gantier from the Hudson Institute of Medical Research to discuss their partnering on the SOF-VAC mRNA vaccine enhancer.

Introducing the partnership, Mautner said: "We formally established our strategic partnership with the Hudson Institute in November 21 via our Pharmorage subsidiary, basically as a way of diversifying our portfolio and gaining exposure to the mRNA therapeutics field.”

Through this venture, Noxopharm secures exclusive licensing rights to pioneering technologies produced by Gantier’s team that are pertinent to the development of next-generation mRNA vaccines and medications.

Circumvents side effects

Gantier stated that one of the key issues with mRNA therapeutics, such as vaccines, is circumventing toxic inflammation.

Roughly 60% of patients experience side effects like headaches, fever, or arm swelling post-mRNA vaccine administration.

Gantier’s lab spearheads research into the interaction between mRNA therapeutics and molecular immune sensors.

“Rock solid” patent

In terms of intellectual property, both entities have fortified their positions.

Mautner added: "We have a robust patent protection strategy in place to protect our assets.

"And we are closely working with a very well-regarded and highly sophisticated team of team of patent attorneys who look after our interests in this area."

“Our approach is to protect our assets from the ground up. And we want our IP protection to be as rock solid as possible.

Burgeoning sector

This collaboration aims not just to catapult Noxopharm into the burgeoning RNA therapeutics sector.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The sector is valued at around 42 billion US dollars in 2021 and predicted to surge to some 128 billion US dollars by 2030, but also to pioneer new medications for inflammation-centric diseases, including psoriasis, arthritis, diabetes, and heart disease.

With several pivotal studies in progress, the partners express optimism about unveiling further medical innovations in the coming months.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.